{"filing":{"accession_number":"0001193125-26-268874","cik":"0001121404","ticker":"SNYNF","company_name":"Sanofi","form":"6-K","filing_date":"2026-06-12","report_date":null,"primary_document":"d25308d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526268874/d25308d6k.htm"},"events":[{"id":12144,"run_id":10709,"accession_number":"0001193125-26-268874","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Sanofi announced its 2026 global employee stock purchase plan (Action 2026), which will issue up to 9.8 million new shares to approximately 75,000 employees across 52 countries at a 20% discount to market price. The issuance represents material dilution to existing shareholders through increased share count and reduced earnings per share.","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-12","form":"6-K","submitted_at":null,"items":[{"id":8923,"accession_number":"0001193125-26-268874","item_number":"EX-99.1","item_title":"d25308dex991.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"This press release announces Sanofi's 2026 global employee stock purchase plan (\"Action 2026\"), which will issue up to 9,816,701 new shares to approximately 75,000 employees across 52 countries at a 20% discount to market price. The issuance of new equity securities at a discount to fair value is a dilutive event material to shareholders, as it increases share count and reduces earnings per share. The scale (nearly 10 million shares, representing material dilution) and the discount mechanism (20% below market) make this a material capital event that would affect a reasonable investor's assessment of ownership and per-share metrics.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:19:10.367485+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":12145,"run_id":10709,"accession_number":"0001193125-26-268874","anchor_item_number":"EX-99.2","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The European Commission approved Sarclisa (isatuximab) subcutaneous formulation administered via an on-body injector for multiple myeloma treatment. This regulatory approval expands the commercial availability and delivery method of the existing marketed drug, representing a material operational and commercial development for Sanofi's oncology portfolio.","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-12","form":"6-K","submitted_at":null,"items":[{"id":8924,"accession_number":"0001193125-26-268874","item_number":"EX-99.2","item_title":"d25308dex992.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces European Commission approval of Sarclisa (isatuximab) subcutaneous formulation administered via an on-body injector (OBI) for multiple myeloma treatment. The disclosure is a regulatory milestone and product approval event that expands the commercial availability and delivery method of an existing marketed drug. While not a discrete M\u0026A, financial, or governance event, the regulatory approval of a new formulation with demonstrated patient preference and clinical efficacy represents a material operational and commercial development for Sanofi's oncology portfolio, affecting the product's market potential and patient treatment options.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:19:10.367485+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":12146,"run_id":10709,"accession_number":"0001193125-26-268874","anchor_item_number":"EX-99.3","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Sanofi terminated the MOBILIZE phase 3 clinical trial of riliprubart in CIDP patients following an interim analysis showing insufficient efficacy. The failure of the phase 3 study represents a material setback to the company's pipeline and R\u0026D direction, affecting investor assessment of future revenue potential.","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-12","form":"6-K","submitted_at":null,"items":[{"id":8925,"accession_number":"0001193125-26-268874","item_number":"EX-99.3","item_title":"d25308dex993.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Sanofi announced termination of the MOBILIZE phase 3 clinical trial of riliprubart in CIDP patients following an interim analysis showing insufficient efficacy. This is a material operational/strategic event affecting the company's pipeline and R\u0026D direction. While no safety signals were identified and no significant financial cost is incurred, the failure of a phase 3 study is a significant setback for a drug candidate that would materially affect investor assessment of the company's pipeline prospects and future revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:19:10.367485+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8923,"accession_number":"0001193125-26-268874","item_number":"EX-99.1","item_title":"d25308dex991.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"This press release announces Sanofi's 2026 global employee stock purchase plan (\"Action 2026\"), which will issue up to 9,816,701 new shares to approximately 75,000 employees across 52 countries at a 20% discount to market price. The issuance of new equity securities at a discount to fair value is a dilutive event material to shareholders, as it increases share count and reduces earnings per share. The scale (nearly 10 million shares, representing material dilution) and the discount mechanism (20% below market) make this a material capital event that would affect a reasonable investor's assessment of ownership and per-share metrics.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:19:10.367485+00:00","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-12"},{"id":8924,"accession_number":"0001193125-26-268874","item_number":"EX-99.2","item_title":"d25308dex992.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces European Commission approval of Sarclisa (isatuximab) subcutaneous formulation administered via an on-body injector (OBI) for multiple myeloma treatment. The disclosure is a regulatory milestone and product approval event that expands the commercial availability and delivery method of an existing marketed drug. While not a discrete M\u0026A, financial, or governance event, the regulatory approval of a new formulation with demonstrated patient preference and clinical efficacy represents a material operational and commercial development for Sanofi's oncology portfolio, affecting the product's market potential and patient treatment options.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:19:10.367485+00:00","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-12"},{"id":8925,"accession_number":"0001193125-26-268874","item_number":"EX-99.3","item_title":"d25308dex993.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Sanofi announced termination of the MOBILIZE phase 3 clinical trial of riliprubart in CIDP patients following an interim analysis showing insufficient efficacy. This is a material operational/strategic event affecting the company's pipeline and R\u0026D direction. While no safety signals were identified and no significant financial cost is incurred, the failure of a phase 3 study is a significant setback for a drug candidate that would materially affect investor assessment of the company's pipeline prospects and future revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:19:10.367485+00:00","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-06-12"}]}